Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Eur Rev Med Pharmacol Sci ; 24(16): 8585-8591, 2020 08.
Article in English | MEDLINE | ID: covidwho-745634

ABSTRACT

Some surface proteins of the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can bind to the hemoglobin molecule of an erythrocyte, which leads to the destruction of the structure of the heme and the release of harmful iron ions to the bloodstream. The degradation of hemoglobin results in the impairment of oxygen-carrying capacity of the blood, and the accumulation of free iron enhances the production of reactive oxygen species. Both events can lead to the development of oxidative stress. In this case, oxidative damage to the lungs leads then to the injuries of all other tissues and organs. The use of uridine, which preserves the structure of pulmonary alveoli and the air-blood barrier of the lungs in the course of experimental severe hypoxia, and dihydroquercetin, an effective free radical scavenger, is promising for the treatment of COVID-19. These drugs can also be used for the recovery of the body after the severe disease.


Subject(s)
Coronavirus Infections/pathology , Oxidative Stress , Pneumonia, Viral/pathology , Betacoronavirus , COVID-19 , Coronavirus Infections/drug therapy , Coronavirus Infections/virology , Cytokines/metabolism , Erythrocytes/cytology , Erythrocytes/metabolism , Erythrocytes/virology , Free Radical Scavengers/pharmacology , Free Radical Scavengers/therapeutic use , Hemoglobins/metabolism , Humans , Oxidative Stress/drug effects , Pandemics , Pneumonia, Viral/drug therapy , Pneumonia, Viral/virology , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/physiology , Quercetin/analogs & derivatives , Quercetin/pharmacology , Quercetin/therapeutic use , Reactive Oxygen Species/metabolism , SARS-CoV-2 , Uridine/pharmacology , Uridine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL